Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What “realistic” driver is left in the short term to increase the Stock Price?
The canary in the mine will be if Dr. William DeGrado sticks around to Salvage B and thus the SP from where it is???? If he doesn’t remain on as an advisor, it will tell you all you need to know going forward.
From today's PR: "We believe Brilacidin holds tremendous promise as a differentiated antiviral drug candidate and plan to continue its development in this area of great opportunity and unmet need.”
Who's "we" believe ....
Is it really just you Leo?
Is it the RBL's or trial leads?
Is "we" Leo and William DeGrado???
Leo in your next PR over hype rant .... tell us, the long term investors who "we" is!
Attach credibility to your next PR with a quote from someone other than yourself.
Don't just blame LEO, although William DeGrado is a late addition, his expertise and navigation was not profitable or wise. I would like to hear from the "expert" on where we go from here????
Yes, Dr. DeGrado please analyze what the F happened here???
SI 426
Artificial Intelligence computer analysis favorability towards B
Multiple MOA's
Did Leo F-UP again with the no win trial design like Purisol???
Leo you can't work hard enough or long enough to make up for this failure....
Nice Preprint Thanks DrBones!
Just to make it clear it was released on 11/05/2021. William DeGrado is the 3rd author.
Brilacidin, a COVID-19 Drug Candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E and NL63 through targeting both the virus and the host cell
Yanmei Hu, Hyunil Jo, William DeGrado, View ORCID ProfileJun Wang
doi: https://doi.org/10.1101/2021.11.04.467344
B Refresher course enclosed
Read this again, published in Viruses:
https://www.mdpi.com/1999-4915/13/2/271/htm
and this presentation from ASV 2021 40th Annual Meeting:
https://static1.squarespace.com/static/5715352e20c647639137f992/t/60f98b02dee5a72cfce0c44e/1626966816579/GMU+ASV+2021+Brilacidin+talk+fv+7.21.21.pdf
Pfizer’s Covid Pill Not as great as they claim... big surprise
Pfizer’s Covid Pill Might Not be as Great as They’re Saying — GripRoom
Pfizer claims their drug reduces hospitalization by 89%. But their study has some issues.
All the headlines are saying “Game changer” or “The beginning of the end of the pandemic.” Pfizer’s results might have been near the same, or even worse than Merck’s had they run their trial on actual high-risk patients.
My fingers are crossed, something now not moving to a long drawn out Phase III without a BP funding and partnership.
Leo, what's your next move assuming great top line data? I'm betting you have negotiated something "in advance", some kind of deal with BP "if" Brilacidin delivers on solid efficacy and safety in the COVID-19 trial.
Aurinia Pharmaceuticals currently has no debt on its balance sheet!
Aurinia has been operating solely on its equity investment and has NO debt burden, unique among biotech startups. This is BIG Positive as it would greatly reduce the risk around any Big Pharma (BMY) or other BP/Biotech suiters investing in the early stage launch of Lupkynis lupus nephritis - a Blockbuster oral therapy.
$1.5 - $2 BILLION per year are the Reported estimated peak sales!!! A Blockbuster for Patients too.
I agree 100 percent. A quality air tight analysis with no holes first and foremost!!! … could they be understaffed? Missing self imposed delivery deadlines reflects badly on them and has this long annoyed!!!
Glad to have AUPH to offset this dissatisfaction.
An already FDA Fast Tracked approximately 120 patient trial.
Come on Leo, put a little more pressure on the data management hacks!
To deliver on their self Appointed delivery window instead of letting them make it a moving target !
Ground Hog Day.. just like in the move, Leo seen his shadow so two more weeks of waiting! Lol
Hope it was worth the huge investments of our time and money????
Honestly, I wouldn’t count on Monday, more like “hopefully” by Friday. If sooner, Great!!!
Been here since 2013.
Let’s hope William DeGrado has been heavily involved in the last few months.
AUPH stock should soar, many potential individual buyers were caught off guard in the last minutes of trading on Friday. Hopefully we hear that there is a bidding war going on with two or more big pharmaceutical’s?
Check back in 3 hours like at 9:20,
AUPH … hopefully IPIX follows suit this week!!!
Bottom line, B is being used for COVID-19! “Following receipt of such requests, the Company has supplied Brilacidin to relevant hospitals for individual patient use, with the FDA granting the treating physician permission for the emergency administration of Brilacidin.”
Spread the word… consider and request Brilacidin when all else fails. Too many COVID patients are dying everyday in the ICU’s, why the heck not try it if/when the monoclonal cocktail fails or going to be on a ventilator!
Not if the architect is , PhD, William DeGrado
William F. "Bill" DeGrado, Ph.D., is the Professor of Pharmaceutical Chemistry at the University of California, San Francisco (UCSF) [1] and a member of the National Academy of Sciences.
Leo please sell it all if given the chance… you’re driving me crazy and I want to put this all in the rear view mirror ASAP! Your probably the luckiest Pharma CEO in world history with the pandemic breathing life back into B and you still fumble the ball out of bounds! Prove me wrong!
Pete, I have 25 plus years in biotech ok... I’ve launched new therapeutics in new startups and worked for the most premiere biotech companies in my career at all levels… I live and breathe it. How about you, You might dabble in stock and read a few articles ie play an expert …chill on your personal attacks! Leo current resume and accomplishments as it stands today wouldn’t land him a Senior Leadership job in any serious biotech or big Pharma company. He’s produced no stock holder value, quite the opposite. He/we could get very lucky with B.
Congress can hold the FDA accountable… #45 held them accountable in Operation Warp Speed. “ “Operation Warp Speed was a federal effort that supported multiple COVID-19 vaccine candidates to speed up development.” There is a huge unmet need for better therapeutics. Leo has been handed an absolute Gift, free trials with a drug he had no funds to support, we were dead in the water with B … then a made to order pandemic for B materialized.
BTW: Leo has never been a good communicator or drug developer, long before he had to keep a lid on it legally. I’ve held this stock for 8 years and there are still what … 3 employees?. No OM indications... the lead up, that was fluff. It’s been held together by a large group of under water investors and a long shot possibility of catching lightening in a bottle with COVID… and that with a lot of luck and fortuitous timing.
That said, I hope Leo can get it done.. have some serious doubts.
Where have you been… already heavily averaged down at .08 cents per share. Lol
What the heck is going on around here… MIA Leo where are you???
Fast Track my %ss!!! Who’s holding the FDA accountable?
I will never ever buy another penny stock… unless this one hits!!! ??
IMO all the stars are aligned for a HUGE $$$ IPIX Buyout anytime now.
Brilacidin's Fast Track Designation for Covid-19
Definition from FDA.Gov
"Fast Track is a process designed to facilitate the development and advance the review of drugs that treat serious conditions, and fill an unmet medical need, based on promising animal or human data. Fast tracking can get important new drugs to the patient earlier. The drug company must request the Fast Track process."
INNOVATION was granted Fast Track for Covid-19 in January 2021! To say Innovation needs to complete a Phase 3 before it can be availalble for use is not accurate.... ever hear of follow up Phase 3 confirmatory trials??? Look that up!
COVID variants, you’re not getting used if ineffective! Amazing opportunities for Brilacidan!
Eli Lilly’s Covid-19 drug bamlanivimab is no longer distributed in 3 states because of a variant, acting FDA director, Woodcock says!
https://endpts.com/lillys-covid-19-drug-bamlanivimab-is-no-longer-distributed-in-3-states-because-of-a-variant/
Are the stars, moon and planet finally aligning????
1. Great timing is everything (check) Huge Unmet Need Worldwide - Brilacidin has been granted FDA Fast Track designation and currently is being evaluated in a randomized, placebo-controlled Phase 2 clinical trial in hospitalized COVID-19 patients.
2. Who you know is game changer (check) Dr. William DeGrado and his connections from UCSF
3. Having an Therapeutic with it's novel MOA (check) "Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture”— in the journal Viruses that supports Brilacidin’s potential as a COVID-19 treatment."
Vaccines cannot handle some of the newer mutations ... look it up.... they are not all that we all hoped for! The Covid-19 Vaccines cannot keep up with the many mutations that are taking place as we speak.
Brilacidin is a very unique therapeutic that can handle all comers and is not subject to resistance.
if Dr. DeGrado is helping to direct these studies (he has a vested interest is an understatement), we will have the worlds best expert advice for Brilacidan's success in COVID-19 you could find.
Ridgeback's is not virucidal like Brilacidin, theirs prevents replication according the article.
Think about it, wouldn't you find it better to kill the virus and stop it before it has a chance to replicate????
Brilacidin's MOA is superior, it will not become COVID-19 resistant because it kills the virus by rupturing the cell membrane.... end of story. A dead virus cannot replicate, and cannot become resistant.
426 SI
Yeah it's a HEMI.... 426 SI under the hood!!!
Remind me again ... what does the Remdesivir have under their hood?
CYDY is DONE finished, toast as a COVID-19 therapeutic! CYDY Stock dropped 28% today.. that's all you need to know and their futile PR to put a positive SPIN of their ad hoc analysis of the trial failed too.
Cytodyn's CD12 leronlimab Phase 3 trial on COVID-19 severe-to-critical patients failed.
* failed to meet both its primary endpoint and all secondary endpoints with any statistical significance.
One less competitor in the therapeutic arena.
Brilacidin to the rescue! GTA
define a "nice spike" and I'll be there!!!! We can also bring in psychologist and have a group therapy session on why we held onto this stock for so long! LOL
Will Leo uplist asap?
Fidelity... can't initiate any trades at this time???? Anyone else?
How exactly do you lock up your shares???
A first mover advantage is so important, that therapy gains a competitive advantage by being the first to bring a new product to the market. First movers typically establish strong brand recognition and customer loyalty. The advantages of first movers include time to develop economies of scale—cost-efficient ways of producing or delivering a product. The market share ($$$) is seldom challenged by a later to market "me too" efficacy or not having an Adverse Event profile superiority.
ALL BP and Biotech institutions know that.
Update 6.2 Million PRE-Market ... lots of new eyes on this one finally!
If they do sell, let's hope they maintain some discipline and don't sell low in the rally.
5.2 million shares PRE-Market ... nobody can predict where we end today but it's going/gaining to be another great day to own AVXL!